Voyager Therapeutics (VYGR) Depreciation & Amortization (CF) (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Depreciation & Amortization (CF) data on file, last reported at $932000.0 in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 8.09% year-over-year to $932000.0; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (down 11.07% YoY), and the FY2025 full-year result was $4.1 million, down 12.77% from the prior year.
• Depreciation & Amortization (CF) declined to $932000.0 in Q1 2026, from $1.1 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.8 million in Q1 2022 to a low of $843000.0 in Q4 2022.
• A 5-year average of $1.2 million and a median of $1.1 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) surged 120.72% in 2022 and plunged 61.77% in 2023, its largest moves.
• Tracing VYGR's Depreciation & Amortization (CF) over 5 years: stood at $843000.0 in 2022, then surged by 53.5% to $1.3 million in 2023, then decreased by 24.27% to $980000.0 in 2024, then advanced by 11.12% to $1.1 million in 2025, then declined by 14.42% to $932000.0 in 2026.
• Business Quant data shows VYGR's Depreciation & Amortization (CF) at $932000.0 in Q1 2026, $1.1 million in Q4 2025, and $932000.0 in Q3 2025.